Daniel Soffer, MD
Disclosures: Advisor or Review Panel Member-Amgen-PCSK9 inhibitor trial review|Advisor or Review Panel Member-akcea therapeutics-Familial Chylomicronemia Syndrome, orphan drug program|Advisor or Review Panel Member-Medicure-novel statin (pitavastatin magnesium)|Speakers’ Bureau-akcea therapeutics-Disease state (Familial Chylomicronemia Syndrome)|Speakers’ Bureau-sanofi-Disease state (Familial Hypercholesterolemia)|Advisor or Review Panel Member-regeneron-PCSK9 inhibitor program
No Bio Available.